U.S. FDA declines to approve Avenue's IV formulation of painkiller
Reuters
Published Jun 14, 2021 08:15AM ET
Updated Jun 14, 2021 05:45PM ET
(Removes reference to tramadol as a non-opioid in headline, paragraph 1, 2)
(Reuters) -Avenue Therapeutics Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its intravenous formulation of painkiller tramadol for a second time, sending its shares tumbling about 38%.
The health regulator in October declined to approve the intravenous formulation of the painkiller, stating it was not safe for the intended population.
The agency said on Monday the delayed and unpredictable onset of analgesia - relief from pain - with intravenous (IV) tramadol did not support its benefit as a monotherapy to treat patients with acute pain.
There was also insufficient data to support that IV tramadol was safe and effective in combination with other drugs, FDA said in its decision that came in more than two months after the scheduled date of April 12.
H.C. Wainwright analyst Joseph Pantginis, however, says that IV tramadol could still have a path forward.
The FDA did not mention any "chemistry, manufacturing and controls (CMC)" issues in its complete response letter, Avenue said, adding that it disagreed with the agency's decision and would continue to seek regulatory approval for IV tramadol.
Tramadol was approved in the United States in 1995 as a non-controlled analgesic, under the trade name of Ultram, to be sold by drugmaker Johnson & Johnson (NYSE:JNJ).
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.